STAT+: A Sign Biotech Is Back? Four Drugmakers Go Public, Raising Nearly $1 Billion in All

Why It Matters

The influx of capital revives funding pipelines for innovative therapies and signals restored investor appetite for high‑risk, high‑reward biotech ventures.

Key Takeaways

• Agomab, Eikon, Spyglass, Veradermics raised ~$1B total.
• Generate Biomedicines filed IPO paperwork.
• Biotech IPOs rebounded after 2021 peak decline.
• Only 11 biotech IPOs in 2025, historic low.
• Investor appetite signals sector turnaround.

Pulse Analysis

The biotech IPO market has been dormant since the 2021 boom, hampered by tightening monetary policy, heightened regulatory scrutiny, and a perception that drug development yields low returns. Venture capitalists shifted toward private funding rounds, leaving public listings as a rarity. This environment produced just 11 public offerings last year, a figure not seen in a decade and a half, underscoring the sector’s financing challenges.

The recent quartet of listings—Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics—collectively secured nearly $1 billion, a substantial infusion that dwarfs the prior year’s totals. Each company targets distinct therapeutic niches: Agomab focuses on antibody‑based oncology, Eikon on precision oncology platforms, Spyglass on rare‑disease gene therapies, and Veradermics on dermatologic biologics. Their successful IPOs not only provide runway for clinical trials but also validate market confidence in differentiated pipelines, encouraging other private biotech firms to consider public routes.

For investors, the resurgence offers a renewed avenue to participate in breakthrough drug development while diversifying portfolios beyond traditional pharma. However, the sector remains vulnerable to policy shifts, pricing pressures, and the inherent binary outcomes of clinical success. Continued IPO activity will likely hinge on sustained pipeline progress and clearer regulatory pathways, making the next 12‑month window critical for assessing whether this revival is a fleeting spike or the foundation of a longer‑term market correction.